Mirum Pharmaceuticals, Inc. MIRM Investments - Amortized Cost Basis

Investments - Amortized Cost Basis at other companies

Rhythm Pharmaceuticals, Inc.RYTM

——

Ionis PharmaceuticalsIONS

——

BridgeBio PharmaBBIO

——

Merck & Co.MRK

——

AmgenAMGN

——

AbbVieABBV

——

Other financials

Income statement

See full

Revenue$159.9M+43.3%

Operating income-$789.5M-5,100%

Net income-$790.2M-5,284%

EPS (diluted)-$13.43-4,377%

Balance sheet

See full

Cash & equivalents$261.5M+43.5%

Total debt$13.5M+56.4%

Total equity$242.5M+4.0%

Total assets$890.9M+29.1%

Cash flow

See full

Operating cash flow-$228.8M-11,566%

CapEx$664.0K+1,520%

Free cash flow-$229.4M-11,360%

Valuation

See full

Market cap$6.53B+152%

Enterprise value$6.28B+162%

P/S11.5×+4.6×

Profitability

See full

Operating margin-139.8%-168pp

Net margin-140.2%-169pp

FCF margin-30.3%—

Returns & leverage

See full

Return on equity-335.8%-377pp

Debt / equity0.1×0.0×

Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s investments - amortized cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s investments - amortized cost basis?: Mirum Pharmaceuticals, Inc. (MIRM) reported investments - amortized cost basis of $357.25M in Q1 2026.